The effect of supplemental beta-carotene on immunologic indices in patients with AIDS: A pilot study

D. A. Fryburg, R. J. Mark, B. P. Griffith, P. W. Askenase, Thomas F Patterson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Patients with the acquired immunodeficiency syndrome (AIDS) are characterized by a decrease in the number oft helper cells, a defect that is linked to the impaired immunologic competence, Vitamin A and its dietary precursor, beta-carotene, increase absolute T helper cell counts as well as indices oft cell function in both human and animal models. To determine if short-term beta-carotene treatment affects T lymphocyte subsets in patients with AIDS, a single-blind, non-randomized clinical trial of beta-carotene was performed in seven patients with AIDS. Enrollment criteria included no evidence of: a) active opportunistic infection; b) greater than 1 kilogram change in weight in the month preceding enrollment; c) chronic diarrhea or malabsorption; and d) hepatic disease or significant anemia. Beta-carotene was given with meals in two divided doses of 60 mg/day for four weeks; this was followed by no therapy for six weeks. Samples for total white blood cell, lymphocyte and T lymphocyte subset counts were measured at baseline, at the end of four weeks of treatment and another six weeks after treatment had stopped. P24 antigen, beta-2 microglobulin and liver function tests were also measured. All subjects tolerated the treatment well without evidence of toxicity. In response to beta-carotene, total lymphocyte counts rose by 66 percent (.05 < p < .10), and CD4+ cells rose slightly, but insignificantly, in the entire group. In all three of the patients who had baseline CD4+ cells greater than 10/μl, however, the mean absolute increase in CD4+ cells in response to beta-carotene was 53 ± 10 cells/μl (p < .01). Six weeks off beta-carotene treatment, the absolute CD4+ cell count returned to pretreatment levels (p < .01). No change was observed in CD8+ cells. P24 antigen and beta-2 microglobulin did not change during treatment. These preliminary observations suggest that short term treatment with beta-carotene may increase CD4+ cell counts in patients with AIDS who have greater than 10 cells/μl.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalYale Journal of Biology and Medicine
Volume68
Issue number1-2
StatePublished - 1995
Externally publishedYes

Fingerprint

beta Carotene
Acquired Immunodeficiency Syndrome
beta 2-Microglobulin
T-cells
Lymphocytes
Lymphocyte Count
T-Lymphocyte Subsets
Therapeutics
CD4 Lymphocyte Count
Immunocompetence
Antigens
Liver Function Tests
Opportunistic Infections
Helper-Inducer T-Lymphocytes
Vitamin A
Liver
Toxicity
Meals
Anemia
Diarrhea

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The effect of supplemental beta-carotene on immunologic indices in patients with AIDS : A pilot study. / Fryburg, D. A.; Mark, R. J.; Griffith, B. P.; Askenase, P. W.; Patterson, Thomas F.

In: Yale Journal of Biology and Medicine, Vol. 68, No. 1-2, 1995, p. 19-23.

Research output: Contribution to journalArticle

Fryburg, D. A. ; Mark, R. J. ; Griffith, B. P. ; Askenase, P. W. ; Patterson, Thomas F. / The effect of supplemental beta-carotene on immunologic indices in patients with AIDS : A pilot study. In: Yale Journal of Biology and Medicine. 1995 ; Vol. 68, No. 1-2. pp. 19-23.
@article{6d87ca1dd7ac4db08e9e9868e9e7d9d4,
title = "The effect of supplemental beta-carotene on immunologic indices in patients with AIDS: A pilot study",
abstract = "Patients with the acquired immunodeficiency syndrome (AIDS) are characterized by a decrease in the number oft helper cells, a defect that is linked to the impaired immunologic competence, Vitamin A and its dietary precursor, beta-carotene, increase absolute T helper cell counts as well as indices oft cell function in both human and animal models. To determine if short-term beta-carotene treatment affects T lymphocyte subsets in patients with AIDS, a single-blind, non-randomized clinical trial of beta-carotene was performed in seven patients with AIDS. Enrollment criteria included no evidence of: a) active opportunistic infection; b) greater than 1 kilogram change in weight in the month preceding enrollment; c) chronic diarrhea or malabsorption; and d) hepatic disease or significant anemia. Beta-carotene was given with meals in two divided doses of 60 mg/day for four weeks; this was followed by no therapy for six weeks. Samples for total white blood cell, lymphocyte and T lymphocyte subset counts were measured at baseline, at the end of four weeks of treatment and another six weeks after treatment had stopped. P24 antigen, beta-2 microglobulin and liver function tests were also measured. All subjects tolerated the treatment well without evidence of toxicity. In response to beta-carotene, total lymphocyte counts rose by 66 percent (.05 < p < .10), and CD4+ cells rose slightly, but insignificantly, in the entire group. In all three of the patients who had baseline CD4+ cells greater than 10/μl, however, the mean absolute increase in CD4+ cells in response to beta-carotene was 53 ± 10 cells/μl (p < .01). Six weeks off beta-carotene treatment, the absolute CD4+ cell count returned to pretreatment levels (p < .01). No change was observed in CD8+ cells. P24 antigen and beta-2 microglobulin did not change during treatment. These preliminary observations suggest that short term treatment with beta-carotene may increase CD4+ cell counts in patients with AIDS who have greater than 10 cells/μl.",
author = "Fryburg, {D. A.} and Mark, {R. J.} and Griffith, {B. P.} and Askenase, {P. W.} and Patterson, {Thomas F}",
year = "1995",
language = "English (US)",
volume = "68",
pages = "19--23",
journal = "Yale Journal of Biology and Medicine",
issn = "0044-0086",
publisher = "Yale Journal of Biology and Medicine Inc.",
number = "1-2",

}

TY - JOUR

T1 - The effect of supplemental beta-carotene on immunologic indices in patients with AIDS

T2 - A pilot study

AU - Fryburg, D. A.

AU - Mark, R. J.

AU - Griffith, B. P.

AU - Askenase, P. W.

AU - Patterson, Thomas F

PY - 1995

Y1 - 1995

N2 - Patients with the acquired immunodeficiency syndrome (AIDS) are characterized by a decrease in the number oft helper cells, a defect that is linked to the impaired immunologic competence, Vitamin A and its dietary precursor, beta-carotene, increase absolute T helper cell counts as well as indices oft cell function in both human and animal models. To determine if short-term beta-carotene treatment affects T lymphocyte subsets in patients with AIDS, a single-blind, non-randomized clinical trial of beta-carotene was performed in seven patients with AIDS. Enrollment criteria included no evidence of: a) active opportunistic infection; b) greater than 1 kilogram change in weight in the month preceding enrollment; c) chronic diarrhea or malabsorption; and d) hepatic disease or significant anemia. Beta-carotene was given with meals in two divided doses of 60 mg/day for four weeks; this was followed by no therapy for six weeks. Samples for total white blood cell, lymphocyte and T lymphocyte subset counts were measured at baseline, at the end of four weeks of treatment and another six weeks after treatment had stopped. P24 antigen, beta-2 microglobulin and liver function tests were also measured. All subjects tolerated the treatment well without evidence of toxicity. In response to beta-carotene, total lymphocyte counts rose by 66 percent (.05 < p < .10), and CD4+ cells rose slightly, but insignificantly, in the entire group. In all three of the patients who had baseline CD4+ cells greater than 10/μl, however, the mean absolute increase in CD4+ cells in response to beta-carotene was 53 ± 10 cells/μl (p < .01). Six weeks off beta-carotene treatment, the absolute CD4+ cell count returned to pretreatment levels (p < .01). No change was observed in CD8+ cells. P24 antigen and beta-2 microglobulin did not change during treatment. These preliminary observations suggest that short term treatment with beta-carotene may increase CD4+ cell counts in patients with AIDS who have greater than 10 cells/μl.

AB - Patients with the acquired immunodeficiency syndrome (AIDS) are characterized by a decrease in the number oft helper cells, a defect that is linked to the impaired immunologic competence, Vitamin A and its dietary precursor, beta-carotene, increase absolute T helper cell counts as well as indices oft cell function in both human and animal models. To determine if short-term beta-carotene treatment affects T lymphocyte subsets in patients with AIDS, a single-blind, non-randomized clinical trial of beta-carotene was performed in seven patients with AIDS. Enrollment criteria included no evidence of: a) active opportunistic infection; b) greater than 1 kilogram change in weight in the month preceding enrollment; c) chronic diarrhea or malabsorption; and d) hepatic disease or significant anemia. Beta-carotene was given with meals in two divided doses of 60 mg/day for four weeks; this was followed by no therapy for six weeks. Samples for total white blood cell, lymphocyte and T lymphocyte subset counts were measured at baseline, at the end of four weeks of treatment and another six weeks after treatment had stopped. P24 antigen, beta-2 microglobulin and liver function tests were also measured. All subjects tolerated the treatment well without evidence of toxicity. In response to beta-carotene, total lymphocyte counts rose by 66 percent (.05 < p < .10), and CD4+ cells rose slightly, but insignificantly, in the entire group. In all three of the patients who had baseline CD4+ cells greater than 10/μl, however, the mean absolute increase in CD4+ cells in response to beta-carotene was 53 ± 10 cells/μl (p < .01). Six weeks off beta-carotene treatment, the absolute CD4+ cell count returned to pretreatment levels (p < .01). No change was observed in CD8+ cells. P24 antigen and beta-2 microglobulin did not change during treatment. These preliminary observations suggest that short term treatment with beta-carotene may increase CD4+ cell counts in patients with AIDS who have greater than 10 cells/μl.

UR - http://www.scopus.com/inward/record.url?scp=0029564165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029564165&partnerID=8YFLogxK

M3 - Article

C2 - 8748463

AN - SCOPUS:0029564165

VL - 68

SP - 19

EP - 23

JO - Yale Journal of Biology and Medicine

JF - Yale Journal of Biology and Medicine

SN - 0044-0086

IS - 1-2

ER -